Fig. 1.

Recombinant aldosterone (Aldo) inhibits in vitro myogenesis. (A) Mouse C2C12 myoblasts (MBs) were differentiated into myotubes (MTs) with 2% horse serum after exposure to the indicated concentrations of recombinant Aldo for 3 days. MTs were stained with anti-myosin heavy chain (MyHC) antibody while nuclei were counterstained with 4,6-diamidino-2-phenyindole (DAPI). Quantitative results per field are presented (n=4). (B) Quantitative reverse-transcription polymerase chain reaction and (C) Western blot analyses of myogenin, myocyte enhancer factor 2C (Mef2C), and/or MyHC in C2C12 cells without or with 2% horse serum in the presence of 100 nM Aldo for 3 days (n=3). (D) The directional migration and (E) viability of mouse C2C12 MBs were assessed by a Boyden chamber system and cell counting kit-8 (CCK-8) assay after exposure to the indicated concentrations of Aldo for 6 and 24 hours, respectively (n=5). Scale bars: 100 μm (A) and 50 μm (D). Data are expressed as mean±standard error of the mean. OD, optical density. ^aP<0.05 vs. control or MB; ^bP<0.05 vs. untreated MT.